A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Liquidia Corp stock. As of the latest transaction made, Two Sigma Advisers, LP holds 273,400 shares of LQDA stock, worth $3.28 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
273,400
Previous 299,800 8.81%
Holding current value
$3.28 Million
Previous $3.61 Million 11.81%
% of portfolio
0.01%
Previous 0.01%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$11.35 - $16.73 $299,640 - $441,672
-26,400 Reduced 8.81%
273,400 $4.03 Million
Q4 2023

Feb 14, 2024

SELL
$5.77 - $12.19 $482,948 - $1.02 Million
-83,700 Reduced 21.83%
299,800 $3.61 Million
Q3 2023

Nov 14, 2023

SELL
$6.27 - $8.15 $574,959 - $747,355
-91,700 Reduced 19.3%
383,500 $2.43 Million
Q2 2023

Aug 14, 2023

SELL
$6.63 - $9.9 $651,729 - $973,170
-98,300 Reduced 17.14%
475,200 $3.73 Million
Q1 2023

May 15, 2023

SELL
$5.72 - $7.91 $728,156 - $1.01 Million
-127,300 Reduced 18.16%
573,500 $3.96 Million
Q4 2022

Feb 14, 2023

SELL
$4.68 - $6.54 $1.02 Million - $1.42 Million
-216,900 Reduced 23.64%
700,800 $4.46 Million
Q3 2022

Nov 14, 2022

BUY
$3.73 - $8.39 $1.76 Million - $3.95 Million
471,100 Added 105.49%
917,700 $4.99 Million
Q2 2022

Aug 15, 2022

BUY
$3.37 - $7.55 $706,689 - $1.58 Million
209,700 Added 88.52%
446,600 $1.95 Million
Q1 2022

May 16, 2022

BUY
$5.14 - $7.38 $230,786 - $331,362
44,900 Added 23.39%
236,900 $1.7 Million
Q4 2021

Feb 14, 2022

BUY
$2.71 - $5.17 $520,320 - $992,640
192,000 New
192,000 $935,000
Q4 2020

Feb 16, 2021

SELL
$2.6 - $5.79 $589,160 - $1.31 Million
-226,600 Closed
0 $0
Q3 2020

Nov 16, 2020

BUY
$4.34 - $8.28 $828,072 - $1.58 Million
190,800 Added 532.96%
226,600 $1.12 Million
Q2 2020

Aug 14, 2020

BUY
$4.86 - $11.44 $173,988 - $409,552
35,800 New
35,800 $301,000

Others Institutions Holding LQDA

About Liquidia Corp


  • Ticker LQDA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 64,362,300
  • Market Cap $772M
  • Description
  • Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil inje...
More about LQDA
Track David A. Siegel's Portfolio

Track David A. Siegel Portfolio

Follow David A. Siegel (Two Sigma Advisers, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.